Disease-Modifying Therapies in Alzheimer’s and Neurodegenerative Disorders

  • Free

Why attend?

The landscape for Alzheimer’s disease diagnosis has changed significantly over the past decade, but there is still only one conditionally FDA-approved medication. Despite extensive research and many expensive clinical trials, more than 200 investigational programs have failed or been abandoned in the past 10 years alone. New treatments are needed to prevent Alzheimer’s, delay its onset, slow its progression, improve cognition, and reduce behavioral disturbances.

Important advances have been made in our understanding of the underlying pathology and ability to measure in vivo biomarkers to make possible early detection and confirmation of the disease. However, there remain several challenges in successfully bringing new disease-modifying treatments through the clinical development process.

Key Learning Objectives

  • Historical and current trends in Alzheimer’s disease
  • Main reasons for clinical trial failures
  • Current scientific hypotheses and related therapeutic approaches
  • When treatment should begin in relation to the underlying disease
  • Study design options
  • Identifying the right sites, patients, and study partners
  • Patient retention and other keys to running long-term trials
  • The role of adjudication committees


Select a speaker to learn more

Andreas Schreiner, M.D.
Vice President, Medical Affairs Neuroscience and Analgesia

Dr. Schreiner has considerable experience as a clinician and investigator as well as more than 20 years of global experience within the pharmaceutical industry and clinical research environment. In his role, he is responsible for providing strategic planning, coordination, knowledge, and expertise in neuroscience and analgesia for projects and/or standalone consultative services for development programs covering entire product lifecycles.

Dr. Schreiner is a certified psychiatrist and neurologist. He studied medicine at the Universities of Heidelberg and Mannheim, Germany, and completed residencies in the University Department of Neurology and in Psychiatry at the Central Institute of Mental Health, both in Mannheim, Germany.

Next speaker
Chris Foster, Ph.D.
Project Manager, Neuroscience

Dr. Foster has worked for more than 10 years in the basic and clinical research fields focused on aging, Mild Cognitive Impairment, and Alzheimer’s disease. He is responsible for managing clinical trials within the neuroscience division of Premier Research where he oversees the study life cycle and ensures clinical trials meet key metrics such as timelines and patient recruitment/retention goals. Dr. Foster received his Ph.D. in Cognitive Neuroscience from the University of North Carolina at Chapel Hill.

Next speaker

Contact us

If you want to become a sponsor, speak at an event or become a partner, leave a message at the "Partner with us" page and we will contact you as soon as possible.